Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial -

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Musculo-skeletal disorders
Summary
Study (n=618) found at follow-up of 62 months, 307 event-free survival events were reported (153 with MAP vs 154 with MAPIE). The results do not support addition of ifosfamide+ etoposide; administration was associated with increased toxicity without improving event-free survival
UKMi comment
The MAP group received cisplatin, doxorubin and methotrexate postoperatively, whilst the MAPIE group received all three of the above plus ifosfamide and etoposide (MAPIE).
Related links: